[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Liquid Biopsy Market by Product & Service (Reagents, Instruments, and Service), Cancer Type (Lung, Breast, Colorectal, Prostate, Liver, and Others), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [CtDNA], and Other Biomarkers) - Global Opportunity Analysis and Industry Forecast, 2017-2023

April 2017 | 164 pages | ID: LE44613D752EN
Allied Market Research

US$ 5,540.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Liquid biopsies are non-invasive blood tests that detect tumor DNA & RNA fragments and circulating tumor cells (CTCs), which are released into the blood from the primary tumors and metastatic sites. It is a minimally invasive technology for the detection of molecular biomarkers, excluding expensive or invasive procedures. The global liquid biopsy market accounted for $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023.
Liquid biopsy is a simple and precise alternative to surgical biopsies, which allows physicians & surgeons to detect & treat cancer at an early stage and acquire tumor information through blood samples. These biopsies are particularly significant as they help the physician to understand the molecular changes and dynamics of cancer. Moreover, cancer recurrence is expected to be understood through well-timed liquid biopsies.
Surge in prevalence of cancer, advantages of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, and favorable government initiatives supplement the market growth. However, alternatives to liquid biopsies and unclear reimbursement & regulation scenario impede the growth. Furthermore, increase in pre-screening programs for cancer detection provide lucrative opportunity for the market players.
The liquid biopsy market is segmented based on product & service, cancer type, circulating biomarker, end user, and geography. Based on product & service, it is divided into reagents, instruments, and services. On the basis cancer type, it is classified into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancer. According to circulating biomarkers, it is categorized into circulating tumor cell, extracellular vesicle, circulating tumor DNA [ctDNA], and other biomarkers. On the basis of end user, it is classified into hospital & laboratory and government & research centers. Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
KEY PLAYERS PROFILED
  • Biocept, Inc.
  • Qiagen
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics
  • Janssen Diagnostics, LLC.
  • Trovagene Inc.
  • Guardant Health Inc.
  • GRAIL
  • MDX Health SA
KEY MARKET BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the global liquid biopsy market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on cancer types assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Liquid Biopsy Market Key Segments:
By Product & Service
  • Reagents
  • Instruments
  • Services
By Cancer Type
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Other Cancers
By Circulating Biomarker
  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA [CtDNA]
  • Other Biomarkers
By End User
  • Hospitals & Laboratories
  • Government & Academic Research Centers
By Geography
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
The other players in the value chain include (profiles not included in the report)
  • Fraunhofer-Gesellschaft
  • Horizon Discovery
  • Illumina, Inc.
  • Cynvenio
  • Diagnologix
  • Exosome Sciences
  • CyoTrack
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
  1.4.1. Primary research
  1.4.2. Secondary research
  1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS
  3.6.1. Drivers
    3.6.1.1. Increase in demand for safe and non-invasive procedures
    3.6.1.2. Surge in prevalence of cancer worldwide.
    3.6.1.3. Advantages of liquid biopsy tests
  3.6.2. Restraints
    3.6.2.1. Limitations associated with liquid biopsy testing
    3.6.2.2. Lack of awareness in developing in underdeveloped regions
  3.6.3. Opportunities
    3.6.3.1. Rise in pre-screening programs for cancer detection using liquid biopsy
    3.6.3.2. Untapped potential of emerging markets

CHAPTER 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

4.1. OVERVIEW
  4.1.1. Market size and forecast
4.2. KITS & REAGENTS
  4.2.1. Key market trends
  4.2.2. Growth factors and opportunities
  4.2.3. Market size and forecast
4.3. PLATFORMS & INSTRUMENTS
  4.3.1. Key market trends
  4.3.2. Growth factors and opportunities
  4.3.3. Market size and forecast
4.4. SERVICES
  4.4.1. Key market trends
  4.4.2. Growth factors and opportunities
  4.4.3. Market size and forecast

CHAPTER 5 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1. OVERVIEW
  5.1.1. Market size and forecast
5.2. CIRCULATING TUMOR CELL (CTC)
  5.2.1. Market size and forecast
5.3. CIRCULATING TUMOR DNA (CTDNA)
  5.3.1. Market size and forecast
5.4. EXTRACELLULAR VESICLES (EVS)
  5.4.1. Market size and forecast
5.5. OTHER BIOMARKERS
  5.5.1. Market size and forecast

CHAPTER 6 LIQUID BIOPSY MARKET, BY CANCER TYPE

6.1. OVERVIEW
  6.1.1. Market Size and Forecast
6.2. LUNG CANCER
  6.2.1. Market size and forecast
6.3. BREAST CANCER
  6.3.1. Market size and forecast
6.4. COLORECTAL CANCER
  6.4.1. Market size and forecast
6.5. PROSTATE CANCER
  6.5.1. Market size and forecast
6.6. LIVER CANCER
  6.6.1. Market size and forecast
6.7. OTHER CANCERS
  6.7.1. Market size and forecast

CHAPTER 7 LIQUID BIOPSY MARKET, BY END USER

7.1. OVERVIEW
  7.1.1. Market size and forecast
7.2. HOSPITAL AND LABORATORY
  7.2.1. Market size and forecast
7.3. GOVERNMENT AND ACADEMIC RESEARCH CENTERS
  7.3.1. Market size and forecast

CHAPTER 8 LIQUID BIOPSY MARKET, BY GEOGRAPHY

8.1. OVERVIEW
  8.1.1. Market size and forecast
8.2. NORTH AMERICA
  8.2.1. Key market trends
  8.2.2. Key growth factors and opportunities
  8.2.3. Market size and forecast
    8.2.3.1. U.S. market size and forecast
    8.2.3.2. Canada market size and forecast
    8.2.3.3. Mexico market size and forecast
8.3. EUROPE
  8.3.1. Key market trends
  8.3.2. Key growth factors and opportunities
  8.3.3. Market size and forecast
    8.3.3.1. Germany market size and forecast
    8.3.3.2. France market size and forecast
    8.3.3.3. UK market size and forecast
    8.3.3.4. Italy market size and forecast
    8.3.3.5. Rest of Europe market size and forecast
8.4. ASIA-PACIFIC
  8.4.1. Key market trends
  8.4.2. Key growth factors and opportunities
  8.4.3. Market size and forecast
    8.4.3.1. Japan market size and forecast
    8.4.3.2. China market size and forecast
    8.4.3.3. Australia market size and forecast
    8.4.3.4. India market size and forecast
    8.4.3.5. South Korea market size and forecast
    8.4.3.6. Taiwan market size and forecast
    8.4.3.7. India market size and forecast
    8.4.3.8. Rest of Asia-Pacific market size and forecast
8.5. LAMEA
  8.5.1. Key market trends
  8.5.2. Key growth factors and opportunities
  8.5.3. Market size and forecast
    8.5.3.1. Brazil market size and forecast
    8.5.3.2. Turkey market size and forecast
    8.5.3.3. Saudi Arabia market size and forecast
    8.5.3.4. South Africa market size and forecast
    8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. BIOCEPT, INC.
  9.1.1. Company overview
  9.1.2. Company snapshot
  9.1.3. Operating business segments
  9.1.4. Product portfolio
  9.1.5. Business performance
9.2. QIAGEN N.V.
  9.2.1. Company overview
  9.2.2. Company snapshot
  9.2.3. Operating business segments
  9.2.4. Product portfolio
  9.2.5. Business performance
9.3. F. HOFFMANN-LA ROCHE AG
  9.3.1. Company overview
  9.3.2. Company snapshot
  9.3.3. Operating business segments
  9.3.4. Product portfolio
  9.3.5. Business performance
9.4. BIO-RAD LABORATORIES INC.
  9.4.1. Company overview
  9.4.2. Company snapshot
  9.4.3. Operating business segments
  9.4.4. Product portfolio
  9.4.5. Business performance
9.5. MYRIAD GENETICS
  9.5.1. Company overview
  9.5.2. Company snapshot
  9.5.3. Operating business segments
  9.5.4. Product portfolio
  9.5.5. Business performance
9.6. JANSSEN DIAGNOSTICS, LLC.
  9.6.1. Company overview
  9.6.2. Company snapshot
  9.6.3. Operating business segments
  9.6.4. Product portfolio
  9.6.5. Business performance
9.7. TROVAGENE INC.
  9.7.1. Company overview
  9.7.2. Company snapshot
  9.7.3. Operating business segments
  9.7.4. Product portfolio
  9.7.5. Business performance
9.8. GUARDIANT HEALTH, INC.
  9.8.1. Company overview
  9.8.2. Company snapshot
  9.8.3. Operating business segments
  9.8.4. Product portfolio
  9.8.5. Business performance
9.9. GRAIL
  9.9.1. Company overview
  9.9.2. Company snapshot
  9.9.3. Operating business segments
  9.9.4. Product portfolio
  9.9.5. Business performance
9.10. MDX HEALTH SA
  9.10.1. Company overview
  9.10.2. Company snapshot
  9.10.3. Operating business segments
  9.10.4. Product portfolio
  9.10.5. Business performance

LIST OF TABLES

TABLE 1. GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 2. KITS & REAGENTS BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. PLATFORMS & INSTRUMENTS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. SERVICE LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 6. CTC LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. CTDNA LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. EVS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. OTHER BIOMARKERS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. LUNG CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. BREAST CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. COLORECTAL CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. PROSTATE CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. LIQUID BIOPSY LIVER CANCER MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. LIQUID BIOPSY OTHER CANCERS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. GLOBAL LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 18. HOSPITAL AND LABORATORY LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 19. GOVERNMENT AND ACADEMIC RESEARCH CENTER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 28. EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 29. EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 30. EUROPE LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 34. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 35. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 38. LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 39. LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 40. LAMEA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 41. BIOCEPT, INC.:COMPANY SNAPSHOT
TABLE 42. QIAGEN N.V.:COMPANY SNAPSHOT
TABLE 43. F. HOFFMANN-LA ROCHE AG:COMPANY SNAPSHOT
TABLE 44. BIO-RAD LABORATORIES INC.:COMPANY SNAPSHOT
TABLE 45. MYRIAD GENETICS:COMPANY SNAPSHOT
TABLE 46. JANSSEN DIAGNOSTICS, LLC:COMPANY SNAPSHOT
TABLE 47. TROVAGENE, INC.:COMPANY SNAPSHOT
TABLE 48. GUARDANT HEALTH, INC.:COMPANY SNAPSHOT
TABLE 49. GRAIL:COMPANY SNAPSHOT
TABLE 50. MDX HEALTH SA:COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. GLOBAL LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL LIQUID BIOPSY MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE AND DISTRIBUTION
FIGURE 4. TOP WINNING STRATEGIES: TYPE AND COMPANY
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. GLOBAL LIQUID BIOPSY MARKET: CIRCULATING BIOMARKER SEGMENTATION
FIGURE 12. U.S. LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 15. GERMANY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 17. UK LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 19. REST OF EUROPE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 20. JAPAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 21. CHINA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 22. AUSTRALIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 23. INDIA ONCOLOGY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 25. TAIWAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 26. INDIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 28. BRAZIL LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 29. TURKEY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 30. SAUDI ARABIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 31. SOUTH AFRICA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 32. REST OF LAMEA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)

More Publications

Need Help?

Ask a Question

Market Reports

All Categories